Italian Authorities Investigate Misleading Ads by BAT and Amazon

Apr.18.2023

Italian Authorities Investigate Misleading Ads by BAT and Amazon

Italian authorities investigate misleading ads for BAT's glo hyper X2 on Amazon for potential health risks.

On April 18th, according to a report by Market Watch, the Italian Competition Authority (AGCM) launched an investigation into British American Tobacco (BAT) and Amazon, citing claims that the two companies have been providing misleading information in their advertising for new heated tobacco devices.

The Italian competition watchdog announced that the advertising campaign for the glo hyper X2 product, owned by British American Tobacco, inaccurately suggested that the product is nicotine-free. The advertisement was disseminated on Amazon, and could potentially pose health risks to some consumers, particularly minors.

Currently, neither British American Tobacco nor Amazon have responded to the issue.

Further reading:

British American Tobacco responds to 2FIRSTS: Testing of disposable e-cigarettes in the UK is a valid concern.

British and American tobacco companies are suspected of initiating an anti-ban movement against electronic cigarettes in Australia. The related videos have been removed.

The IBVTA says that any harm reduction claims made by BAT should be questioned.

Legal Expert Op-Ed: BAT Cannot Serve as Enforcement Police for E-Cigarettes

BAT has launched a pop-up store called "Glo studio" in South Korea to kick off a new product experience event.

References:

Amazon and British American Tobacco are under investigation in Italy for their promotion of heated tobacco devices through advertising.

#Legislation #Africa #Uganda #British American Tobacco (BAT)

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

China Tobacco Regulation Shift：Policy Updates and Market Impact

China Tobacco Regulation Shift：Policy Updates and Market Impact

Ispire Q2 FY2026 revenue falls to $20.3M as it trims lower-quality customers; A/R down nearly 20%

Ispire Q2 FY2026 revenue falls to $20.3M as it trims lower-quality customers; A/R down nearly 20%

Ispire reported a sharp year-on-year revenue decline in Q2 FY2026 as it shifted away from lower-quality customers, while cutting operating expenses and narrowing its net loss. The company also highlighted improved collections, with net accounts receivable down nearly one-fifth since June 30, 2025, alongside ongoing manufacturing and technology initiatives.

Feb.09 by 2FIRSTS.ai

Kansas Senate approves tougher vape rules to target unlicensed products and child-directed ads

Kansas Senate approves tougher vape rules to target unlicensed products and child-directed ads

The Kansas Senate approved Senate Bill 355 on Wednesday, aiming to crack down on unlicensed vaping products and eliminate advertisements geared toward children. The bill, backed by major tobacco companies, would impose the same licensing and advertising requirements on e-cigarettes as other nicotine products and require every e-cigarette manufacturer doing business in Kansas to obtain a license, with a $2,500 application fee.

Feb.13 by 2FIRSTS.ai

Six Years of Data Show FDA Clearing PMTA Backlog

Six Years of Data Show FDA Clearing PMTA Backlog

FDA data from FY2020 to FY2025 show how the PMTA system for e-cigarette products evolved after an early surge of submissions created prolonged front-end delays. Millions of applications accumulated at the Acceptance stage before entering substantive review. Since 2023, the number of applications pending acceptance has declined sharply, and industry participants report shorter initial decision timelines in late 2025.

FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks

FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks

During the FDA PMTA roundtable session on “Studies of Adult Benefit,” officials said flavored ENDS must demonstrate “added benefit” over tobacco-flavored products under the APPH standard, including sustained complete switching evidence. Small manufacturers questioned switching benchmarks, study duration, and bridging expectations.

PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries

PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries

During FDA’s Feb 10 PMTA roundtable (manufacturing controls panel), small ENDS manufacturers warned that uncertainty in manufacturing expectations creates existential financial risk. FDA officials reiterated review flexibility is constrained by statutory and scientific boundaries. The panel debated testing standards, documentation requirements, open-system responsibility, supply chain changes, and software updates—highlighting unresolved PMTA challenges for small manufacturers.

France’s ANSES Report Reframes the Vape Debate: Harm Reduction Confirmed, Regulatory Barriers Rising

France’s ANSES Report Reframes the Vape Debate: Harm Reduction Confirmed, Regulatory Barriers Rising

France’s top health agency has confirmed that vaping is less harmful than smoking — but not risk-free — reshaping the country’s regulatory trajectory. As Paris withdraws a proposed vape tax and debates stricter ingredient, emissions and youth-protection rules, the ANSES report signals not prohibition, but tighter technical oversight. For manufacturers, retailers and EU policymakers, France may be previewing Europe’s next phase of nicotine governance.

Related Topics

News

Related Read

Ispire Q2 FY2026 revenue falls to $20.3M as it trims lower-quality customers; A/R down nearly 20%

Ispire Q2 FY2026 revenue falls to $20.3M as it trims lower-quality customers; A/R down nearly 20%

Kansas Senate approves tougher vape rules to target unlicensed products and child-directed ads

Kansas Senate approves tougher vape rules to target unlicensed products and child-directed ads

Six Years of Data Show FDA Clearing PMTA Backlog

Six Years of Data Show FDA Clearing PMTA Backlog

FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks

FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks

PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries

PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries

France’s ANSES Report Reframes the Vape Debate: Harm Reduction Confirmed, Regulatory Barriers Rising

France’s ANSES Report Reframes the Vape Debate: Harm Reduction Confirmed, Regulatory Barriers Rising